Search Results for:
-
S-TARget Seeking $8M for Allergy Vaccine Platform
S-TARget is seeking scientific advice from Germany's Paul-Ehrlich-Institut on clinical trial designBy Cormac Sheridan | BioWorld International | Wednesday, April 10, 2013 -
Activartis in Partnering Talks Armed with Phase II Survival
Alongside the Phase II evidence of safety and efficacy in glioblastoma, Activartis has evidence from academic clinical trials demonstrating the technology is applicable to other tumor typesBy Nuala Moran | BioWorld International | Wednesday, April 10, 2013 -
Epigenetics Now Goes Far Beyond HDAC Inhibitors
For now, the bulk of clinical trials targeting epigenetic mechanisms is still at an early stage...Those clinical trials, he said, will be "the ultimate test of the whole hypothesisBio Perspectives | Tuesday, April 9, 2013 -
Epigenetics Now Goes Far Beyond HDAC Inhibitors
For now, the bulk of clinical trials targeting epigenetic mechanisms is still at an early stage...Those clinical trials, he said, will be "the ultimate test of the whole hypothesisBy Anette Breindl | BioWorld Today | Tuesday, April 9, 2013 -
The Search for Venture Capital Continues to be Challenging
RN-307 was discovered and originally developed by Rinat Neuroscience Corp., a South San Francisco protein therapeutics company that was acquired by Pfizer in 2006. (See BioWorld Today, April 10, 2006.) In a Series C financing Versartis Inc., of Redwood City, Calif., raised $25 million to support clinical trials of its product candidate VRS-317 for growth hormone deficiency in children. (See BioWorld Today, Jan. 16, 2013.) The drug is a once-monthly form of recombinant human growth hormone (HGHBy Peter Winter | BioWorld Insight | Monday, April 8, 2013 -
Geron ESC Assets Regenerate at Asterias Biotherapeutics
The complex asset contribution agreement involves multiple transfers of common stock and warrants, along with patents, regulatory filings and investigational new drug (IND) applications filed with the FDA for Geron's Phase I safety study of oligodendrocyte progenitor (GRNOPC-1) cells in patients with neurologically complete, subacute spinal cord injury – the first FDA-approved ESC clinical trial. (See BioWorld Today, Jan. 26, 2009, and Jan. 27, 2009.) The S-1 represented the first step toBy Marie Powers | BioWorld Today | Friday, April 5, 2013 -
Financings Roundup
Net proceeds will be used to cover costs related to the new drug application for CompleoTRT, making a milestone payment for CompleoTRT, manufacturing scale-up for CompleoTRT and Tefina clinical trialsBioWorld Today | Friday, April 5, 2013 -
AACR Annual Meeting Set to Kick Off in Washington
Jose Baselga, physician-in-chief at Memorial Sloan-Kettering Cancer Center and the chairman of the program committee for the 2013 annual meeting, said in a recorded greeting that the data being presented at the conference span the trajectory from basic biology to clinical trial resultsBy Anette Breindl | BioWorld Today | Friday, April 5, 2013 -
Study Shows Road Taken by Broadly Neutralizing Antibody
Haynes and his colleagues said they hope that by understanding the road traveled by the broadly neutralizing antibody their subject produced, they will be able to develop a series of antigens that can be used to induce broadly neutralizing antibodies via a series of vaccinations – though Haynes' response when asked when such a vaccine might enter clinical trials was succinct: "I don't knowBy Anette Breindl | BioWorld Today | Thursday, April 4, 2013 -
Alzheimer's Guidance Shows Challenges Facing FDA, Industry
Intended as a conversation starter, the draft lays out a potential approach to select subjects with early AD and those at risk of developing the disease for enrollment in clinical trials...According to the guidance, the FDA can't formally endorse specific diagnostic frameworks yet because of "the need for an assessment of sensitivity and specificity in identifying patients who do have actual AD in clinical trialsBio Perspectives | Wednesday, April 3, 2013 -
Chance Observation Triggers Idea to Treat Polycystic Kidneys
2DG is already in clinical trials for some types of cancer, and we think that it might provide a way to interfere with the progression of this diseaseBy Sharon Kingman | BioWorld International | Wednesday, April 3, 2013 -
Themis Plans Trials for Dengue and Chikungunya Vaccines
Themis Bioscience GmbH is planning to begin clinical trials of viral vaccine candidates to protect against dengue virus and chikungunya virus infections before year-end, following successful preclinical proof of concept studiesBy Cormac Sheridan | BioWorld International | Wednesday, April 3, 2013 -
Other News To Note
Anaeropharma Science Inc., of Tokyo, initiated a Phase I trial of APS001F in U.S. patients with advanced or metastatic solid tumors whose disease is no longer responsive to available treatments. The dose-escalation trial is designed to evaluate the safety, tolerability and efficacy of APS001F, a living recombinant bifidobacterium designed to express the cytosine deaminase gene in tumors. The therapy is expected to limit the systemic toxicity of the antitumor agent 5-FU. ConvergenceBioWorld International | Wednesday, April 3, 2013 -
HIV Antigens Identified Can Jump-Start Broad Antibodies
He estimated that such clinical trials are five years away at leastBy Anette Breindl | BioWorld Today | Wednesday, April 3, 2013 -
Clinic Roundup
Tengion Inc., of Winston-Salem, N.C., said the firm's clinical trial application was accepted in Sweden to start a Phase I trial testing its Neo-Kidney Augment in up to five patients with advanced chronic kidney diseaseBioWorld Today | Tuesday, April 2, 2013 -
Other News To Note
Separately, BioMarin said it submitted a clinical trial application with the UK's Medicines and Healthcare Products Regulatory Agency for BMN-190, a recombinant human tripeptidyl peptidase 1 , in neuronal ceroid lipofuscinosis Type 2 (NCL-2), a form of Batten diseaseBioWorld Today | Tuesday, April 2, 2013 -
Milo Aims Follistatin Therapy at Muscular Dystrophy
The next step "is to get data from the clinical trial," he addedBy Marie Powers | BioWorld Today | Tuesday, April 2, 2013 -
Research Looking to Discover Genetic Keys to a Longer Life
In response, the FDA's Center for Drug Evaluation and Research issued draft guidance in February on the development of drugs in early stage Alzheimer's disease, which lays out a potential approach to select subjects with early AD and those at risk of developing the disease for enrollment into clinical trialsBy Peter Winter | BioWorld Insight | Monday, April 1, 2013 -
Alzheimer's Guidance Shows Challenges Facing FDA, Industry
Intended as a conversation starter, the draft lays out a potential approach to select subjects with early AD and those at risk of developing the disease for enrollment in clinical trials...According to the guidance, the FDA can't formally endorse specific diagnostic frameworks yet because of "the need for an assessment of sensitivity and specificity in identifying patients who do have actual AD in clinical trialsBy Mari Serebrov | BioWorld Today | Monday, April 1, 2013 -
Themis Plans Trials for Dengue And Chikungunya Vaccines
Themis Bioscience GmbH is planning to begin clinical trials of viral vaccine candidates to protect against Dengue virus and Chikungunya virus infections before year-end, following successful preclinical proof of concept studiesBy Cormac Sheridan | BioWorld Today | Monday, April 1, 2013
Category
Current Filters
- xclinical trials
Related Keywords
Categories
- x BioWorld Today (9744)
- x BioWorld International (1951)
- x BioWorld Insight (1198)
- x Bio Perspectives (295)
- x State of the Industry Report (131)
- x BioWorld Genomics Review (58)
- x Top 25 Drug Report (43)
- x BioWorld Snapshots (29)
- x Biotech Innovations (17)
- x Market-Leading Biotech Drugs (12)
- x RNAi Report (11)
- x BioWorld Phase III Report (7)
- x Executive Compensation Report (4)
- x Recorded (4)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.